Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
By Bhanvi Satija (Reuters) -Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion,...
By Bhanvi Satija (Reuters) -Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion,...
By Andrea Shalal WILMINGTON, Delaware (Reuters) -The White House on Saturday rejected comments made by...
MOSCOW (Reuters) – Russian Defence Minister Sergei Shoigu said in footage published by his ministry...
By Utkarsh Shetti and Supantha Mukherjee (Reuters) -Network giant Cisco is planning to restructure its...
By Chris Prentice and Huw Jones NEW YORK/LONDON (Reuters) -Global equities rose on Friday, with...
By Jonathan Stempel and Dietrich Knauth NEW YORK (Reuters) -New York Attorney General Letitia James...
By David Shepardson WASHINGTON (Reuters) -The White House on Friday touted the U.S. government’s plan...
By Jonathan Stempel (Reuters) – Amazon.com was sued in a proposed U.S. class action accusing...
By Dawn Chmielewski (Reuters) -Walt Disney is harnessing artificial intelligence to power a new advertising...
LONDON (Reuters) – Investors dumped U.S. and real estate shares and bought Chinese stocks in...